Production (Stage)
Eupraxia Pharmaceuticals Inc.
EPRX.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -26.22M | -25.50M | -28.22M | -27.00M | -30.37M |
| Total Depreciation and Amortization | 180.80K | 171.70K | 158.40K | 159.30K | 155.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.89M | 2.08M | -123.50K | -2.12M | 874.10K |
| Change in Net Operating Assets | -7.72M | -6.76M | -1.82M | 3.21M | 7.02M |
| Cash from Operations | -29.88M | -30.01M | -30.00M | -25.76M | -22.32M |
| Capital Expenditure | -266.40K | -104.20K | -109.30K | -76.60K | -72.10K |
| Sale of Property, Plant, and Equipment | 29.10K | 29.10K | 28.50K | 28.50K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -237.40K | -75.20K | -80.80K | -48.10K | -72.10K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -9.10M | -9.12M | -9.14M | -4.56M | -64.30K |
| Issuance of Common Stock | 32.16M | 54.92M | 23.22M | 39.52M | 44.12M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 23.06M | 45.80M | 14.08M | 34.96M | 44.05M |
| Foreign Exchange rate Adjustments | -1.40M | -1.96M | 107.00K | -264.60K | 315.50K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -8.45M | 13.76M | -15.90M | 8.89M | 21.98M |